NEW YORK, May 30, 2013 /PRNewswire/ -- PHARMACEUTICAL EXECUTIVE magazine's May cover ranks Pharma's 50 top global pharmaceutical companies by revenues and examines five trends that shape current sales performance across the geographies where the pharma group competes.
For the thirtieth year in a row, PHARMACEUTICAL EXECUTIVE, the industry's premier publication, features a ranking by sales of the top 50 pharma companies worldwide.
An accompanying trends feature based on the Pharm Exec survey data was written by Waseem Noor, Vice-President with IMS Consulting Group and leads the global strategy and portfolio analysis team and Michael Kleinrock, Director of Research Development at the IMS Institute for Healthcare Informatics.
See info graphics and data embedded in the Pharma 50 story at http://tinyurl.com/opqev7y
ANY SURPRISES? Rx success of global generic firms as they benefit from innovative portfolio diversification.
Pharm Exec's 2013 ranking of the top 50 pharma companies worldwide finds few variations from last year. The notable exception is the Rx success of global generic firms as they benefit from innovative portfolio diversification: Teva is nipping at the heels of Eli Lilly, at just one slot short of the top 10, while Ranbaxy joins the Pharma 50 list for the first time. Another finding is that, while the cumulative effect of patent expiries on industry sales remains significant, the impact is not across the board. Only a small set of companies—BMS, in particular, which drops to 17th in global Rx sales, from 11th last year—have been affected by loss of exclusivity, contributing disproportionately to weaker overall industry sales performance over the past several years.
See complete story online: http://tinyurl.com/opqev7y
EDITOR WILLIAM LOONEY ON PHARMACEUTICAL EXECUTIVE'S PHARMA 50 COVER STORY: An enduring truth is the startling lack of concentrated market power in pharmaceuticals. What has not changed since we began compiling the Pharma 50 in 2000 is the top 10 still comprise less than 50 percent of the global market (their 2012 global share is 42 percent, compared to 43 percent in 2007). Other industries less reputationally vulnerable than pharma see much more concentration at the top; certainly this is true in the payer community, where governments increasingly hold sway. Even in the patent protected market, the core competency of Big Pharma, the top 10 players' share remained at 52 percent in 2012, the same level it was in 2007. The bottom line? For pharma, business is still an intensely competitive game of chance.
See William Looney's comments online: http://tinyurl.com/opqev7y
PHARMACEUTICAL EXECUTIVE Pharmaceutical Executive probes the interface of business practice and public policy for the global biopharmaceutical, vaccine and medical device industries. PharmExec's editorial remit covers strategy in the"c-suite" as well as regulatory and legal actions; sales promotion and marketing; R&D; finance; human resources; pricing and market access; and new technology. Published by Advanstar Communications, PharmExec's editorial content is available in the award-winning monthly print edition as well as in a number of digital platforms.
For more information: contact: Marylyn Donahue, 212-951-6742
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.
SOURCE Advanstar Communications